Solvay Announces Strategic Partnership with HUYA to Access new Drug Candidates from China
News May 19, 2009
Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global codevelopment of biopharmaceutical product opportunities originating in China.
Through this agreement, Solvay Pharmaceuticals will gain access to HUYA's comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area.
As some of these molecules are already in advanced stages of development in China, the partnership will help Solvay Pharmaceuticals speed up its early discovery activities as well as increase the company's chances for successfully developing new therapies as safety or efficacy information is already available for some of these molecules.
The pace and quality of China's innovation in the life sciences have led to an increase in new product opportunities. Through key collaborations with China's leading academic and commercial organizations, HUYA has gained access to these opportunities to enable and accelerate their worldwide development and commercialization.
HUYA has thereby built a most comprehensive Chinese compound portfolio, including a significant number of product candidates targeting cardiovascular diseases to which Solvay Pharmaceuticals will have access under this strategic partnership.
"We look forward to working with HUYA and its highly qualified Chinese partners to identify innovative new molecules and develop them into break-through new therapies for patients and physicians around the globe," said Werner Cautreels, PhD, CEO of Solvay Pharmaceuticals. "We believe that through this partnership, we will be able to speed up our R&D activities by gaining access to compounds that could be introduced in more advanced stages of early development."
According to Mireille Gingras, PhD, President and CEO of HUYA, "This partnership with Solvay Pharmaceuticals further validates HUYA's model for co-developing in Western markets novel therapeutic compounds sourced from China. Moreover, it leverages our demonstrated capabilities and experience in cardiovascular drug development. We are pleased to partner with Solvay Pharmaceuticals on new opportunities for development."
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE